Wall Street analysts expect Crispr Therapeutics AG (NASDAQ:CRSP) to report earnings of $0.04 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Crispr Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.01 and the highest estimate coming in at $0.07. Crispr Therapeutics reported earnings of ($0.92) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 104.3%. The firm is expected to issue its next quarterly earnings report on Monday, February 24th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year earnings of $0.65 per share for the current year, with EPS estimates ranging from $0.59 to $0.71. For the next fiscal year, analysts expect that the firm will report earnings of ($4.64) per share, with EPS estimates ranging from ($5.38) to ($3.67). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million.
CRSP has been the topic of a number of recent analyst reports. Piper Jaffray Companies restated a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a report on Monday, December 16th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a report on Friday, December 6th. BidaskClub lowered shares of Crispr Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, December 13th. ValuEngine raised shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price objective on shares of Crispr Therapeutics in a research report on Monday, December 23rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $71.38.
Shares of CRSP stock traded down $0.74 during trading hours on Tuesday, reaching $66.01. 999,939 shares of the stock traded hands, compared to its average volume of 985,513. Crispr Therapeutics has a 1-year low of $26.00 and a 1-year high of $74.00. The business has a fifty day moving average price of $64.60 and a 200 day moving average price of $50.48. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $3.68 billion, a PE ratio of -19.19 and a beta of 3.31.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total transaction of $412,500.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the transaction, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 over the last ninety days. 21.40% of the stock is currently owned by insiders.
A number of hedge funds have recently bought and sold shares of CRSP. Nikko Asset Management Americas Inc. grew its position in Crispr Therapeutics by 48.4% in the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after acquiring an additional 906,006 shares in the last quarter. Orbimed Advisors LLC bought a new stake in Crispr Therapeutics in the third quarter worth approximately $21,167,000. Price T Rowe Associates Inc. MD grew its position in Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after acquiring an additional 121,176 shares in the last quarter. Wells Fargo & Company MN grew its position in Crispr Therapeutics by 23.9% in the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after acquiring an additional 116,540 shares in the last quarter. Finally, Balyasny Asset Management LLC bought a new stake in Crispr Therapeutics in the second quarter worth approximately $5,165,000. 49.82% of the stock is owned by institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Straddles
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.